Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Cardiff Oncology Inc. buy Marianka

Start price
24.06.22 / 50%
Target price
Performance (%)
End price
This prediction ended on 26.06.22 with a price of €2.20. With a performance of -1.57%, the BUY prediction for Cardiff Oncology Inc. by Marianka closed slightly in the red. Marianka has 50% into this prediction
Performance without dividends (%)
Name 1w
Cardiff Oncology Inc. 39.251%
iShares Core DAX® -2.661%
iShares Nasdaq 100 4.257%
iShares Nikkei 225® 0.550%
iShares S&P 500 3.276%

According to Marianka what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Standard Investments for future growth
ROE higher than 10% per year
Capable Management
Good culture
Leading role in innovation
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Top 10 in its market
Known brand
Future proof or reliable business model
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
High risks in the balance sheet
High challenges to pay loans and raise capital
High risks for its business
Significant cyclical dependencies

Comments by Marianka for this prediction

In the thread Trovagene diskutieren
Prediction Buy
Perf. (%) -1.57%
Target price 5.000
Ends at 24.06.23

Buy mit Kursziel 5,0

In the thread Trading Trovagene
Prediction Buy
Perf. (%) -1.57%
Target price 5.000
Ends at 24.06.23

Buy beendet